Answers are grounded in this paper and cite their sources.
N6-methyladenosine (m6A), the most prevalent internal modification in eukaryotic RNA, plays a critical role in tumour initiation and progression by regulating RNA splicing, nuclear export, translation, and degradation. Circular RNAs (circRNAs), a class of covalently closed non-coding RNAs generated through back-splicing, have emerged as a prominent focus in cancer research owing to their structural stability and functional versatility. Recent studies have increasingly highlighted the reciprocal regulatory network between m6A modification and circRNAs. This review systematically examines their interplay: m6A modification dynamically modulates circRNA expression by influencing its biogenesis, nuclear export, and degradation, while m6A-modified circRNAs can in turn affect the localization and activity of m6A-modifying enzymes or regulate downstream signaling through mechanisms such as miRNA sponging and protein scaffolding. In urological malignancies, the functional significance of this regulatory axis is becoming increasingly evident. This review focuses on the roles of m6A-modified circRNAs in the malignant phenotypes of renal cell carcinoma, bladder cancer, and prostate cancer, including the promotion of proliferation, metastasis, apoptosis resistance, and drug resistance. Furthermore, it explores their clinical translational potential as diagnostic biomarkers and therapeutic targets, aiming to provide new insights into the precision diagnosis and treatment of urological cancers.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: